Abstract
Thirty-four consenting patients received VM-26 50–100 mg/m2 I.V. before surgical resection of intracerebral tumor, and drug was measured using a high pressure liquid chromatographic technique. Sufficient tumor for analysis was obtained from 29 patients. Brain metastases (13 patients) had higher concentrations of V M-26 than did gliomas (13 patients). Concentrations were comparable in brain metastases and meningiomas (3 patients). Prolonged (24 h) infusion of V M-26 did not appear to result in higher tumor drug concentrations in 5 patients than did rapid (1 h) infusion in 24 patients. Pretreatment with Amphotericin-B 10 mg/m2 12 h and 1 h before VM-26 did not appear to have any effect on VM-26 uptake into 4 intracerebral tumors, although data were limited, and VM-26 concentrations were very high in 1 metastasis. Pretreatment with oral glycerol 500 mg/kg 18 h, 12 h, 6 h, and immediately before I.V. VM-26 may have resulted in increased penetration of VM-26 into 9 tumors, although confirmation is required. Amphotericin-B, glycerol, and operative conditions did not appear to alter VM-26 plasma pharmacokinetics.
Similar content being viewed by others
Abbreviations
- VM-26:
-
4′-demethylepipodophyllotoxin 9-(4-6-O-thenylidene-B-D-glucopyranoside)
- VP-16:
-
4′-demethylepipodophyllotoxin 9-(4-6-O-ethylidene-B-D-glucopyranoside)
References
Stewart DJ, Richard M, Hugenholtz H, Dennery J: VP-16 (VP) and VM-26 (V M) penetration into human brain tumors (BT). Proc Am Assoc Cancer Res 24:133, 1983.
Sklansky BD, Mann-Kaplan RS, Reynolds AF, Rosenblum ML, Walker MD: 4′-demethyl-epipodophyllotoxin-B-D-thenylidene glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 33:460–467, 1974.
Kessinger A, Lemon HM, Foley JF: VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep 63: 511–512, 1979.
Gerosa MA, Di Stefano E, Olivi A: VM-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: preliminary report. Surgical neurology 15:128–134, 1981.
Maroun JA, Stewart DJ, Young V, Belanger R, Crook AF: Effectiveness of VM-26 in non-small cell carcinoma of the lung (NSCLL) with central nervous system (CNS) metastases. Preliminary results. Proc Am Soc Clin Oncol 1:140, 1982.
Shapiro WR: The chemotherapy of intracerebral vs subcutaneous murine gliomas. Arch Neurol 30:222–226, 1974.
Creaven PJ, Allen LM: PTG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol and Therap 18:227–233, 1975.
Sessa C, D'Incalci M, Farina P, Rossi C, Cavalli F, Mangioni C, Garattini S: Pharmacokinetics of VM-26 after 60 minutes or 24 hours continuous infusion. Proc Amer Assoc Cancer Res 23:128, 1982.
Rausa L, D'Alessandro N, Dusonchet L, Gebbia N, Sanguedolce R, Crescimanno M, Crosta L, Flandina C, Leto G, Tumminello FM: Pharmacological studies on VM-26 (teniposide). Chemioterapia 1:130–136, 1982.
Broggini M, Colombo T, D'Incalci M: Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice. Cancer Treat Rep 67:555–559, 1983.
Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Research 42:2474–2479, 1982.
Rosenblum M, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL: Penetration of methylglyoxal bis (guanylhydrazone) into intracerebral tumors in humans. Cancer Research 41:459–462, 1981.
Stewart DJ, Lu K, Benjamin RS, Leavens M, Luna M, Yap HY, Loo TL: Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neuro.Oncol 1:139–144, 1983.
Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL: Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Research 40:3163–3166, 1980.
Groothuis DR, Fischer JM, Vick NA, Bigner DD: Comparative permeability of different glioma models to horseradish peroxidase. Cancer Treat Rep 65 (Suppl 2):13–18, 1981.
Stewart DJ, Richard M, Hugenholtz H, Dennery J, Belanger R, Gerin-Lajoie J, Mompetit V, Nundy D, Prior J, Hopkins HS: Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neuro-Oncol 2:133–139, 1984.
Stewart DJ, Benjamin RS, Luna M, Seifert WE, Loo TL: Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother & Pharm 10:51–54, 1982.
Medoff J, Medoff G, Goldstein MN, Schlessinger D, Kobayashi GS: Amphotericin-B-induced sensitivity to actinomycin-D in drug-resistant HELA cells. Cancer Res 35:2548–2552, 1975.
Medoff G, Kwan CN, Schlessinger D, Kobayashi GS: Potentiation of rifampicin, rifampicin analogs, and tetracycline against animal cells by amphotericin-B and polymyxin-B. Cancer Res 33:1146–1149, 1973.
Levin VA, Landahl HD, Freeman-Dove MA: The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier. J Pharmacokin and Biopharm 4:499–519, 1976.
Barry DI, Paulson OB: Amphotericin-B and the blood-brain barrier to methotrexate. Neurosurgery 10:224–226, 1982.
Sterrett PR, Thompson AM, Chapman AL, Matzke HA: The effects of hyperosmolarity on the blood-brain barrier. A morphological and physiological correlation. Brain Res 77:281–295, 1974.
Rapoport SI, Hori M, Klatzo I: Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol 223: 323–331, 1972.
Neuwelt EA, Diehl JT, Vu LH, Hill SA, Michael AJ, Frenkel EP: Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94:449–454, 1981.
Shapiro WR, Voorhies RM, Basler GA, Blasberg RG: Regional methotrexate entry into experimental rat brain tumors as measured by quantitative autoradiography (QAR). Proc Amer Assoc Cancer Res 23:179, 1982.
Neuwelt EA, Pagel M, Barnett P, Glasberg M, Frenkel EP: Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Cancer Res 41:4460–4470, 1981.
Neuwelt EA, Glasberg M, Barnett P, Frenkel EP: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathologic studies. Proc Amer Assoc Cancer Res 24:272, 1983.
Meyer JS, Itoh Y, Okamoto S, Welch KM, Matthew R, Ott EO, Sakaki S, Miyakawa Y, Chabi E, Ericsson AD: Circulatory and metabolic effects of glycerol infusion in patients with recent cerebral infarction. Circulation 51: 701–712, 1975.
Evans WE, Sinkule JA, Crom WR, Dow L, Look T, Rivera G: Pharmacokinetics of teniposide (VM-26) and etoposide (VP-16–213) in children with cancer. Cancer Chemother Pharmacol 7:147–150, 1982.
Stewart DJ, Benvenuto J, Leavens M, Smith R, Cabanillas F, Benjamin RS, Loo Ti Li: Human central nervous system pharmacology of pentamethylmelamine and its metabolites. J Neuro-Oncol 1:357–364, 1983.
Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KD, Burgess MA, Loo TL: Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid. Cancer Research 39:4119–4122, 1979.
Savaraj N, Lu K, Fenn LG, Leavens ME, Stewart DJ, Burgess MA, Benjamin RS, Loo TL: Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone, (AZQ NSC 182986). J Neuro-Oncol 1:15–20, 1983.
Levin VA, Freeman-Dove M, Landahl HD: Permeability characteristics in brain adjacent to tumor in rats. Arch Neurol 32:785–791, 1975.
Levin VA: A pharmacologic basis for brain tumor chemotherapy. Seminars in Oncology 2:57–61, 1975.
Vick NA, Khandekar JD, Bigner DD: Chemotherapy of brain tumors: The ‘blood-brain barrier’ is not a factor. Arch Neurol 34:523–526, 1977.
Booser DJ, Spitzer G, Chiuten DF, Valdivieso M: Epipodophyllotoxins VP-16–213 and VP-16. A phase 1 study of 5-day continuous intravenous infusion (CI) in bronchogenic carcinomas. Proc Amer Soc Clin Oncol 22:508, 1981.
Hasegawa H, Allen JC, Mehta BM, Shapiro WR, Posner JB: Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis. Neurology 29:1280–1286, 1979.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stewart, D.J., Richard, M.T., Hugenholtz, H. et al. Penetration of teniposide (VM-26) into human intracerebral tumors. J Neuro-Oncol 2, 315–324 (1984). https://doi.org/10.1007/BF00178114
Issue Date:
DOI: https://doi.org/10.1007/BF00178114